Pharmaceutical Technology

Pharmaceutical Technology and its European counterpart, PharmTech.com, serve as a trusted resource for in-depth research and expert insights. They cater to scientists, engineers, and managers involved in various aspects of the pharmaceutical and biotechnology sectors, including process development, manufacturing, formulation, drug delivery, active pharmaceutical ingredient (API) synthesis, analytical technology and testing, packaging, IT solutions, outsourcing, and regulatory compliance.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#397541

Indonesia

#30639

Health/Biotechnology and Pharmaceuticals

Traffic sources

Monthly visitors

Articles

Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing

Nov 19, 2024 | pharmtech.com | Feliza Mirasol

Clinical-stage biotechnology company Alentis Therapeutics (Alentis), which specializes in developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced that it has raised $181.4 million in Series D financing. The financing was supported by a syndicate of top-tier biotech investors. OrbiMed led the way, with Novo Holdings and Jeito Capital as co-leads.
PTC Therapeutics Gains FDA Approval for AADC Deficiency Gene Therapy

Nov 19, 2024 | pharmtech.com | Feliza Mirasol

FDA announced its approval of eladocagene exuparvovec-tneq (Kebilidi, PTC Therapeutics) on Nov. 14, 2024. Eladocagene exuparvovec-tneqan is an adeno-associated virus vector-based gene therapy for treating adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency (1). According to FDA, Kebilidi is the first FDA-approved gene therapy indicated for this disease.
Frontier Scientific Solutions Plans a Global Free Trade Zone Gateway to Supply Life Sciences Industry on Back of $1.5 Billion Investment

Nov 16, 2024 | pharmtech.com | Feliza Mirasol

Frontier Scientific Solutions, a temperature-controlled storage and transportation company that exclusively serves the life sciences industry, announced on Nov. 13, 2024 that it has established state-of-the-art current good manufacturing practice (CGMP) facilities at Wilmington International Airport (ILM) in North Carolina, United States, and Shannon Airport (SNN) in County Clare, Ireland.
EMA's CHMP Gives Positive Opinion for Use of Lecanemab in Early Alzheimer's Disease

Nov 16, 2024 | pharmtech.com | Felicity Thomas

Eisai Europe and Biogen have received a positive opinion from the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) for the use of their amyloid-beta (Ab) monoclonal antibody (mAb) lecanemab in treating adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD). The positive opinion, announced by Eisai in a Nov. 15.
Newly Opened Innovation Center in New Jersey Gives Avantor Advantage in Solving Life Sciences Challenges

Nov 15, 2024 | pharmtech.com | Feliza Mirasol

Avantor, a provider of mission-critical products and services to the life sciences and advanced technology industries, announced on Nov. 14, 2024 that it has opened its new flagship Bridgewater Innovation Center in Bridgewater, NJ. Spanning 60,000 square feet, the state-of-the-art R&D facility joins the company's network of 13 research and innovation centers globally.
Avantor Sees Future of Opportunities with Growing Development of Next-Gen Biotherapeutics

Nov 15, 2024 | pharmtech.com | Feliza Mirasol

In preparation for the launch of its new innovation center in Bridgewater, NJ, Avantor executives discussed a future full of opportunities for service providers, which will come from a growing number of next-generation biotherapeutics in the development pipeline that are anticipated to reach the market in the near future.
What the US Election Results Mean for Industry, In Vivo CAR-T Applications, and more

Nov 14, 2024 | pharmtech.com | Chris Spivey

Behind the Headlines is a bi-weekly panel discussion examining the latesttrends, readouts, and other factors that drive pharmaceutical news and innovation.Each episode features consultants, venture capitalists, scientists, patient advocates, and journalists discussing the prior weeks' top news while seekingto highlight the more enduring lessons that hide behind the headlines.
Merck and Ginkgo Bioworks' Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

Nov 13, 2024 | pharmtech.com | Feliza Mirasol

Ginkgo Bioworks, a provider of a cell programming platform and biosecurity, announced on Nov. 12, 2024 that it has completed the first milestone of a previously announced partnership (1) with Merck, known as MSD outside of the United States and Canada. Their collaboration aims to improve biologics manufacturing, and, according to the terms of their agreement formed in August 2023, Ginkgo will receive a research milestone payment of $9 million in cash for completing this milestone.
TrakCel's OCELLOS Platform Selected to Support Treatment Management of Five Upcoming Cell Therapy Products

Nov 13, 2024 | pharmtech.com | Feliza Mirasol

TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions, announced on Nov. 12, 2024 that some manufacturers have selected its orchestration platform, OCELLOS, to support the management of five out of seven autologous and matched allogeneic cell therapy products. These products are approved or are expected to be approved in 2024.
Ascend Advanced Therapies Expands US Footprint in New Partnership

Nov 12, 2024 | pharmtech.com | Susan Haigney

Ascend Advanced Therapies announced on Nov. 12, 2024 that it is partnering with EW Healthcare Partners to expand capabilities and invest in infrastructure in the United States. As part of the agreement, EW Healthcare's Advanced BioScience Laboratories (ABL), a biotherapy, oncolytic and viral vector contract development, and manufacturing organization (CDMO) located in Rockville, Md., will become part of Ascend. EW Healthcare will also make capital investment in Ascend.